07:52 AM EDT, 09/05/2025 (MT Newswires) -- CG Oncology ( CGON ) said Friday that updated data from a phase 3 trial of its investigational drug cretostimogene as a monotherapy for patients with high-risk non-muscle invasive bladder cancer showed a "robust" 41.8% complete response rate at 24 months.

The latest data came from a group of patients with high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette Guerin treatment, the company said.

The data "underscores cretostimogene's potential to become a breakthrough backbone treatment for bladder cancer patients," said Ambaw Bellete, president and chief operating officer of CG Oncology ( CGON ).

Shares of the company were up more than 6% in recent premarket activity Friday.